Table 1.
Baseline Demographic, Biochemical, and Histologic Characteristics of Subjects
| Ezetimibe (n = 25) | Placebo (n = 25) | P Value | |
|---|---|---|---|
| Demographics | |||
| Age (years) | 49.0 ± 14.9 | 49.5 ± 13.7 | 0.9139 |
| Female patients | 14 (56%) | 17 (68%) | 0.3821 |
| Weight (kg) | 94.1 ± 18.1 | 91.8 ± 18.9 | 0.6662 |
| Height (m) | 1.7 ± 0.1 | 1.7 ± 0.1 | 0.9837 |
| BMI (kg/m2) | 33.8 ± 5.2 | 32.9 ± 5.1 | 0.5432 |
| White (vs. nonwhite) | 19 (76%) | 21 (84%) | 0.4795 |
| Hispanic (vs. non) | 8 (32.0%) | 9 (36%) | 0.7653 |
| Diabetes | 7 (28%) | 7 (28%) | 1.000 |
| Biochemical profile | |||
| ALT (IU/L) | 51.0 (29.0) | 47.0 (26.0) | 0.9615 |
| AST (IU/L) | 33.0 (23.0) | 32.0 (28.0) | 0.6572 |
| AST:ALT | 0.8 (0.5) | 0.8 (0.4) | 0.7284 |
| Alkaline phosphatase (U/L) | 72.0 (29.0) | 72.0 (37.0) | 0.4584 |
| GGT (U/L) | 49.0 (32.0) | 32.5 (42.0) | 0.4049 |
| Total bilirubin (mg/dL) | 0.5 (0.4) | 0.4 (0.2) | 0.7167 |
| Glucose (mg/dL) | 104.0 (25.0) | 106.0 (41.0) | 0.6504 |
| Insulin (μU/mL) | 23.0 (15.5) | 26.5 (18.0) | 0.2322 |
| Hemoglobin A1C (%) | 5.9 (0.7) | 6.1 (1.0) | 0.7015 |
| FFA (mmol/L) | 0.5 (0.3) | 0.7 (0.3) | 0.2140 |
| HOMA-IR | 6.4 (5.1) | 6.5 (5.7) | 0.2205 |
| Triglycerides (mg/dL) | 152.0 (58.0) | 149.0 (104.0) | 0.5567 |
| Total cholesterol (mg/dL) | 182.0 (25.0) | 170.0 (54.0) | 0.5001 |
| LDL (mg/dL) | 100.0 (32.0) | 90.0 (50.5) | 0.3831 |
| Histology | |||
| Steatosis | 2.0 (2.0) | 3.0 (1.0) | 0.1419 |
| Lobular inflammation | 1.0 (1.0) | 2.0 (1.0) | 0.1658 |
| Ballooning | 1.0 (1.0) | 1.0 (1.0) | 0.6996 |
| Fibrosis | 1.0 (1.0) | 1.0 (3.0) | 0.6891 |
| NAS | 5.0 (2.0) | 5.0 (2.0) | 0.1775 |
Mean ± standard deviation is presented for normally distributed variables, median (interquartile range) for nonnormally distributed variables. The Wilcoxon-Mann-Whitney test was performed on all continuous/ordinal variables, and the chi-squared or Fisher's exact test was performed on all categorical variables.
Abbreviations: BMI, body mass index; LDL, low-density lipoprotein; FFA, free fatty acids; GGT, gamma-glutamyl transferase; HOMA-IR, homeostatic model assessment of insulin resistance; NAS, NAFLD activity score.